a Department of Hematology, Oncology and Tumor Immunology , Charite University Medicine Berlin , Berlin , Germany.
b Department of Neurology , Medical University Innsbruck , Innsbruck , Austria.
Expert Rev Hematol. 2016 Nov;9(11):1081-1091. doi: 10.1080/17474086.2016.1242405. Epub 2016 Oct 21.
Making the diagnosis of secondary CNS involvement in lymphoma can be difficult due to unspecific signs and symptoms, limited accessibility of brain/myelon parenchyma and low sensitivity and/or specifity of imaging and cerebrospinal fluid (CSF) examination currently available. Areas covered: MRI of the total neuroaxis followed by CSF cytomorphology and flow cytometry are methods of choice when CNS lymphoma (CNSL) is suspected. To reduce the numerous pitfalls of these examinations several aspects should be considered. New CSF biomarkers might be of potential diagnostic value. Attempts to standardize response criteria are presented. Expert commentary: Diagnosing CNSL remains challenging. Until diagnostic methods combining high sensitivity with high specifity are routinely introduced, high level of awareness and optimal utilization of examinations currently available are needed to early diagnose this potentially devastating disease.
由于非特异性体征和症状、脑/脊髓实质的有限可达性以及目前可用的影像学和脑脊液 (CSF) 检查的灵敏度和/或特异性低，淋巴瘤继发中枢神经系统（CNS）受累的诊断可能较为困难。
当怀疑中枢神经系统淋巴瘤（CNSL）时，首选方法是进行全中枢神经系统 MRI，随后进行 CSF 细胞学和流式细胞术。为了减少这些检查的众多陷阱，应考虑几个方面。新的 CSF 生物标志物可能具有潜在的诊断价值。目前正在尝试提出标准化反应标准。
诊断 CNSL 仍然具有挑战性。在常规引入具有高灵敏度和高特异性的联合诊断方法之前，需要高度意识到并优化利用目前可用的检查方法，以便早期诊断这种潜在的破坏性疾病。
